IMMP IMMUTEP Ltd IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1506184 · Reporting currency AUD · Fiscal year ends 06/30
Financial factors as of 2025-06-30 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: AUD | FY20252025-06-30 | FY20242024-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | 10.33M | 7.84M |
| R&D expense | 49.78M | 31.47M |
| SG&A expense | 8.64M | 8.85M |
| Interest expense | 37,078 | 30,594 |
| Pretax income | -61.43M | -42.72M |
| Income tax | 0 | 0 |
| Net income | -61.43M | -42.72M |
| EPS (basic) | -0.04 | -0.04 |
| EPS (diluted) | -0.04 | -0.04 |
| Weighted avg. shares (diluted) | 1.46B | 1.20B |
| Balance sheet | ||
| Cash & equivalents | 67.41M | 161.79M |
| Short-term investments | 62.28M | 20.09M |
| Receivables | 9.87M | 7.35M |
| Current assets | 149.10M | 191.35M |
| PP&E, netmay include right-of-use assets (IFRS) | 63,458 | 63,145 |
| Total assets | 156.98M | 201.58M |
| Current liabilities | 12.76M | 10.49M |
| Total liabilities | 13.35M | 12.06M |
| Shareholders' equity | 143.64M | 189.52M |
| Cash flow statement | ||
| Operating cash flow | -62.05M | -34.82M |
| Capital expenditure | 45,769 | 29,215 |
| Free cash flow | -62.10M | -34.85M |
| Investing cash flow | -38.53M | -21.02M |
| Financing cash flow | -525,121 | 95.18M |
| Depreciation & amortization | 2.39M | 2.26M |
| Stock-based compensation | 1.16M | 1.80M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, AUD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.